Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Valneva (VALN – Research Report), Janux Therapeutics Inc (JANX – Research Report) and Kymera Therapeutics (KYMR – Research Report).
Janux Therapeutics Inc (JANX)
In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Janux Therapeutics Inc, with a price target of $64.00. The company’s shares closed last Monday at $49.80.
According to TipRanks.com, Stranahan is a 2-star analyst with an average return of
Janux Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $72.17, a 47.5% upside from current levels. In a report issued on May 9, JonesTrading also maintained a Buy rating on the stock with a price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VALN:
